NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Rating) in a research note issued to investors on Monday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Performance

Shares of NASDAQ NURO opened at $1.79 on Monday. NeuroMetrix has a 52 week low of $1.33 and a 52 week high of $5.89. The stock has a market capitalization of $13.89 million, a P/E ratio of -2.59 and a beta of 2.25. The stock’s fifty day moving average is $1.59 and its 200 day moving average is $2.47.

NeuroMetrix (NASDAQ:NURO – Get Rating) last issued its quarterly earnings results on Thursday, October 20th. The medical device company reported ($0.23) EPS for the quarter. NeuroMetrix had a negative return on equity of 20.37% and a negative net margin of 57.46%. The company had revenue of $1.97 million during the quarter.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NURO. Northern Trust Corp acquired a new stake in shares of NeuroMetrix during the second quarter valued at about $41,000. Virtu Financial LLC acquired a new stake in shares of NeuroMetrix during the first quarter valued at about $78,000. Citadel Advisors LLC boosted its stake in shares of NeuroMetrix by 44.3% during the third quarter. Citadel Advisors LLC now owns 34,699 shares of the medical device company’s stock valued at $97,000 after purchasing an additional 10,652 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of NeuroMetrix by 46.4% during the second quarter. Renaissance Technologies LLC now owns 44,113 shares of the medical device company’s stock valued at $162,000 after purchasing an additional 13,985 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in shares of NeuroMetrix by 11.1% during the third quarter. Vanguard Group Inc. now owns 350,029 shares of the medical device company’s stock valued at $977,000 after purchasing an additional 34,892 shares in the last quarter. Institutional investors own 7.34% of the company’s stock.

About NeuroMetrix

(Get Rating)

NeuroMetrix, Inc, a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies.